Cidara Therapeutics EBITDA vs. Price To Sales
| CDTX Stock | USD 20.40 2.95 16.91% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -24.4 M | Current Value -25.6 M | Quarterly Volatility 24.3 M |
For Cidara Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cidara Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cidara Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cidara Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cidara Therapeutics over time as well as its relative position and ranking within its peers.
Cidara |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cidara Therapeutics. If investors know Cidara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cidara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (23.90) | Revenue Per Share 11.875 | Quarterly Revenue Growth (0.94) | Return On Assets (0.16) | Return On Equity (1.53) |
The market value of Cidara Therapeutics is measured differently than its book value, which is the value of Cidara that is recorded on the company's balance sheet. Investors also form their own opinion of Cidara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cidara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cidara Therapeutics' market value can be influenced by many factors that don't directly affect Cidara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cidara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cidara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cidara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cidara Therapeutics Price To Sales vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cidara Therapeutics's current stock value. Our valuation model uses many indicators to compare Cidara Therapeutics value to that of its competitors to determine the firm's financial worth. Cidara Therapeutics is rated fourth in ebitda category among its peers. It is rated third in price to sales category among its peers . Cidara Therapeutics reported EBITDA of (24.36 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cidara Therapeutics' earnings, one of the primary drivers of an investment's value.Cidara Price To Sales vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Cidara Therapeutics |
| = | (24.36 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Cidara Therapeutics |
| = | 2.67 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Cidara Price To Sales Comparison
Cidara Therapeutics is currently under evaluation in price to sales category among its peers.
Cidara Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cidara Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cidara Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Cidara Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Cidara Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -24.5 M | -25.7 M | |
| Income Before Tax | -22.5 M | -23.6 M | |
| Total Other Income Expense Net | 2 M | 2.1 M | |
| Net Loss | -22.9 M | -24.1 M | |
| Net Loss | -22.9 M | -24.1 M | |
| Net Loss | -26.8 M | -28.2 M | |
| Income Tax Expense | 443 K | 606.8 K | |
| Net Interest Income | 2 M | 2.1 M | |
| Non Operating Income Net Other | 171.9 K | 163.3 K | |
| Interest Income | 2 M | 1 M | |
| Change To Netincome | 4.1 M | 3.9 M | |
| Net Loss | (5.25) | (5.51) | |
| Income Quality | 0.98 | 0.65 | |
| Net Income Per E B T | 1.02 | 0.81 |
Cidara Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cidara Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cidara Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cidara Therapeutics' important profitability drivers and their relationship over time.
Use Cidara Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cidara Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cidara Therapeutics will appreciate offsetting losses from the drop in the long position's value.Cidara Therapeutics Pair Trading
Cidara Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Cidara Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cidara Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cidara Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cidara Therapeutics to buy it.
The correlation of Cidara Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cidara Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cidara Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cidara Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cidara Therapeutics position
In addition to having Cidara Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Information Technology ETFs Thematic Idea Now
Information Technology ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Information Technology ETFs theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Information Technology ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.